Fenofibrate Capsules

  • Hyperlipoproteinemias

Fenofibrate Capsules Generic Name & Formulations

General Description

Fenofibrate 67mg, 134mg, 200mg; caps (micronized).

Pharmacological Class


How Supplied

Contact supplier

Fenofibrate Capsules Indications


Adjunct to diet: in severe hypertriglyceridemia; and to reduce elevated total-C, LDL-C, ApoB, and TG, and to increase HDL-C in primary hyperlipidemia and mixed dyslipidemia.

Fenofibrate Capsules Dosage and Administration


Take with food. Hypertriglyceridemia: 67–200mg/day; adjust in 4–8 week intervals; max 200mg/day. Hypercholesterolemia, dyslipidemia: 200mg/day. Renal impairment (CrCl<50mL/min): initially 67mg/day. Discontinue if inadequate response after 2 months on max dose.


Not established.

Fenofibrate Capsules Contraindications


Severe renal impairment. Dialysis. Active liver disease. Primary biliary cirrhosis. Unexplained persistent liver dysfunction. Gallbladder disease. Nursing mothers.

Fenofibrate Capsules Boxed Warnings

Not Applicable

Fenofibrate Capsules Warnings/Precautions


Renal impairment. Monitor CBCs for first year; monitor liver function, discontinue if ALT (SGPT) levels >3xULN persist. Discontinue if markedly elevated CPK levels, myopathy, or gallstones occur. Pregnancy.

Fenofibrate Capsules Pharmacokinetics

See Literature

Fenofibrate Capsules Interactions


Avoid statins. Potentiates oral anticoagulants (monitor). Allow at least 1 hour before or 4–6 hours after bile acid sequestrants. Caution with immunosuppressants (eg, cyclosporine), other nephrotoxic drugs.

Fenofibrate Capsules Adverse Reactions

Adverse Reactions

Abnormal liver function tests, elevated CPK, respiratory or GI effects, myopathy, cholelithiasis, pancreatitis, increased creatinine, rash; rare: rhabdomyolysis, transient hematologic changes, blood dyscrasias.

Fenofibrate Capsules Clinical Trials

See Literature

Fenofibrate Capsules Note


Formerly known under the brand name Lofibra.

Fenofibrate Capsules Patient Counseling

See Literature